Stoke Therapeutics - STOK Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STOK shares.
View STOK analyst ratings or view top-rated stocks.

7 brokerages have issued 12-month price targets for Stoke Therapeutics' stock. Their STOK share price forecasts range from $9.00 to $35.00. On average, they predict the company's stock price to reach $24.57 in the next twelve months. This suggests a possible upside of 200.8% from the stock's current price.
View analysts price targets for STOK or view top-rated stocks among Wall Street analysts.

Stoke Therapeutics' stock was trading at $9.23 at the beginning of 2023. Since then, STOK stock has decreased by 11.5% and is now trading at $8.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our STOK earnings forecast.

Stoke Therapeutics, Inc. (NASDAQ:STOK) posted its quarterly earnings results on Monday, March, 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.06. The business had revenue of $3.27 million for the quarter, compared to analyst estimates of $2.93 million. Stoke Therapeutics had a negative trailing twelve-month return on equity of 47.38% and a negative net margin of 814.73%.

ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Direxion mRNA ETF (MSGR), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Global X Genomics & Biotechnology ETF (GNOM).ALPS Medical Breakthroughs ETF (SBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Stoke Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (6.22%), Cowen AND Company LLC (1.90%), Deutsche Bank AG (1.90%), Granahan Investment Management LLC (1.40%), M28 Capital Management LP (1.22%) and Geode Capital Management LLC (1.20%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano.
View institutional ownership trends.

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STOK stock can currently be purchased for approximately $8.17.

Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $360.71 million and generates $12.40 million in revenue each year. The company earns $-101,070,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

The company employs 102 workers across the globe.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.